• OPEN AN ACCOUNT
Indian Indices
Nifty
25,423.60 93.35
(0.37%)
Sensex
83,013.96 320.25
( 0.39%)
Bank Nifty
55,727.45 234.15
( 0.42%)
Nifty IT
36,750.25 303.10
( 0.83%)
Global Indices
Nasdaq
46,015.42 236.51
(0.52%)
Dow Jones
6,617.88 9.88
(-0.15%)
Hang Seng
45,342.39 552.01
(1.23%)
Nikkei 225
9,208.37 12.71
(0.14%)
Forex
USD-INR
88.02 0.00
(0.00%)
EUR-INR
104.02 0.00
(0.00%)
GBP-INR
120.02 0.00
(0.00%)
JPY-INR
0.60 0.00
(0.00%)

EQUITY - MARKET SCREENER

Patel Engineering Ltd
Industry :  Construction
BSE Code
ISIN Demat
Book Value()
531120
INE244B01030
44.8929397
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
PATELENG
9.06
3396.93
EPS(TTM)
Face Value()
Div & Yield %
4.44
1
0
 

biogen pharmachem industries ltd
Sun Pharma drops as foreign broker downgrades on valuation, execution risks
Aug 26,2025
The broker cited stretched valuations and slower-than-expected traction in speciality drugs. It flagged concerns around psoriasis drug Ilumya's heavy Medicare exposure, potential pricing pressures, and limited earnings visibility despite strong initial uptake. It warned that a 10% price cut in Ilumya could erode Sun Pharma’s EPS by 4%.

Sun Pharmaceutical Industries is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets.

The company’s consolidated net profit tumbled 19.64% to Rs 2,278.63 crore despite of 10.07% increase in revenue from operations to Rs 13,786.07 crore in Q1 FY26 over Q1 FY25. The drop in profit was primarily due to a one-time exceptional charge of Rs 818 crore during the quarter.